NANOMIX CORPORATION - NNMX STOCK NEWS

Nanomix Corporation (OTCQB: NNMX) has announced the appointment of Dr. Thomas Schlumpberger as its new Chief Executive Officer and Board member, effective immediately. He replaces David Ludvigson, who will assist during the transition and serve as interim CFO. Dr. Schlumpberger brings over 20 years of experience in point-of-care diagnostics, having successfully launched products globally and executed significant sales strategies. The board expressed confidence in Dr. Schlumpberger's ability to accelerate the commercialization of the eLab system, which aims to transform point-of-care diagnostics.

Nanomix Corporation (OTCQB: NNMX) has announced a distribution agreement with Biotron Ltd. to market and distribute its eLab® system in Israel. This collaboration aims to enhance the fight against sepsis with rapid, mobile diagnostics. The eLab system offers quick results, lower costs, and portability, crucial for timely diagnosis. The S1 Panel cartridge provides quantitative results for critical infections, including sepsis. The product has already received CE marking in Europe and UK regulatory approval.

Nanomix Corporation (OTCQB: NNMX) has initiated a clinical validation study at Hospital Clinico San Carlos in Madrid, Spain, to assess the Nanomix eLab® S1 Panel for detecting critical infections like sepsis in emergency settings. Led by Dr. Juan González del Castillo, the study aims to enhance diagnostic capabilities and patient outcomes. The eLab system offers rapid results in approximately 12 minutes, significantly faster than traditional methods. The S1 Panel has already received CE marking and UK MHRA registration, further validating its potential impact on patient care.

Nanomix Corporation (OTCQB: NNMX) has received IVDR certification for its eLab analyzer, allowing it to market within the EU under new regulations. The eLab system, which offers rapid, accurate, and portable diagnostics, meets the IVDR standards, enhancing patient protection and ensuring reliable IVDs. This certification, following the CE mark for the S1 assay panel, positions Nanomix for long-term success in the EU market. The system aims to improve healthcare delivery by providing diagnostics at the point of care, crucial in managing critical infections.

Nanomix Corporation (OTCQB: NNMX) has received European CE mark designation for its eLab S1 assay panel, enabling faster diagnostic results by utilizing whole blood samples instead of plasma. This innovation allows quicker testing in emergency settings, improving accessibility and patient outcomes. The eLab S1 can provide results for critical infections like sepsis within approximately 12 minutes, significantly reducing the wait time compared to existing solutions. The company emphasizes this system's role in enhancing mobile, point-of-care diagnostics.

Nanomix Corporation (OTCQB: NNMX) has successfully upgraded to the OTCQB® Venture Market, enhancing its visibility and liquidity among investors. This milestone is essential as the company promotes its Nanomix eLab® system, a mobile point-of-care diagnostic platform. The OTCQB provides transparent trading for entrepreneurial firms, requiring up-to-date financial reporting and management certification. Nanomix's innovative diagnostics aim to facilitate quicker clinical decision-making, particularly for critical infections and SARS-CoV-2 detection.

Nanomix Corporation (OTCBB: NNMX) announced it has achieved the CE mark for its eLab COVID-19 rapid antigen test, confirming its compliance with European health standards. This rapid test delivers results in just 15 minutes from an anterior nasal swab, enhancing point-of-care diagnostic capabilities. The announcement emphasizes the significance of this milestone in validating their testing technology and strengthening their product lineup, which includes the S1 Critical Infection Panel.

Nanomix Corporation (OTC: NNMX, NNMXD) has announced the appointment of Vidur Sahney as Chief Operating Officer. With over 20 years of experience, Mr. Sahney will oversee operations, including manufacturing and assay development. Additionally, the company has relocated its headquarters to a larger 9,325 square foot facility in San Leandro, California, which is 50% larger and half the cost of the previous site. These changes aim to enhance operational efficiency and support Nanomix's growth in point-of-care diagnostics.

Nanomix Corporation (OTC-PINK: NNMXD) has entered a $3 million securities purchase agreement with GHS Investments, LLC. This marks a significant transition for Nanomix from development to commercial operations. GHS, known for investing in promising small-cap companies, is expected to be a valuable partner. The agreement allows Nanomix to sell up to $3 million of common stock to GHS over several months. Nanomix specializes in mobile, point-of-care diagnostics, aiming to enhance healthcare delivery with rapid diagnostic solutions.